<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medalphabet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский алфавит</journal-title><trans-title-group xml:lang="en"><trans-title>Medical alphabet</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2078-5631</issn><issn pub-type="epub">2949-2807</issn><publisher><publisher-name>ООО «Альфмед»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33667/2078-5631-2024-34-42-46</article-id><article-id custom-type="elpub" pub-id-type="custom">medalphabet-4145</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>Коморбидное течение неалкогольной жировой болезни печени и остеопороза</article-title><trans-title-group xml:lang="en"><trans-title>Comorbid flow non-alcoholic fatty liver disease and osteoporosis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0461-2691</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фомина</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Fomina</surname><given-names>L. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Фомина Людмила Артуровна, д.м.н., доцент, профессор кафедры факультетской терапии</p><p>Тверь</p></bio><bio xml:lang="en"><p>Fomina Lyudmila A., DM Sci (habil.), associate professor, professor at Depnt of Faculty Therapy</p><p>Tver</p><p> </p></bio><email xlink:type="simple">Ludmifom@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Тверской государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Tver State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>24</day><month>01</month><year>2025</year></pub-date><volume>0</volume><issue>34</issue><issue-title>Практическая гастроэнтерология (3)</issue-title><fpage>42</fpage><lpage>46</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Фомина А.А., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Фомина А.А.</copyright-holder><copyright-holder xml:lang="en">Fomina L.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-alphabet.com/jour/article/view/4145">https://www.med-alphabet.com/jour/article/view/4145</self-uri><abstract><p>Неалкогольная жировая болезнь печени (НАЖБП) одно из самых распространенных хронических заболеваний печени. Отмечается ее коморбидное течение с различными патологиями. Установлено, что при НАЖБП нередко выявляются нарушения состояния костной ткани. </p><sec><title>Цель исследования</title><p>Цель исследования. Уточнить влияние НАЖБП на состояние костной ткани, зависимость ее изменений и выраженности патологического процесса в печени.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Обследовано 98 женщин, средний возраст 53,3±6,24 года. У всех лиц проводилось клиническое обследование, подсчитывался индекс массы тела, выполнялись ультразвуковое исследование (УЗИ) брюшной полости, двухэнергетическая рентгеновская абсорбциметрия (DXA) поясничного отдела позвоночника (ПОП) и шейки бедра (ШБ), эзофагогастродуоденоскопия, биохимический анализ крови. Все пациенты были разделены на 3 группы: первая группа состояла из 47 человек со стеатозом печени, вторая – включала 25 человек со стеатогепатитом. В контрольную группу вошло 26 женщин с результатами биохимических показателей крови в пределах референсных значений и неизмененными данными УЗИ печени.</p></sec><sec><title>Результаты</title><p>Результаты. Анализ клинических симптомов показал присутствие астенического синдрома/хронической усталости у всех больных с НАЖБП, при этом выраженность симптомов возрастала при стеатогепатите. По данным DХA средние значения Т-критерия и в ШБ, и в ПОП достоверно не отличались у пациентов со стеатозом печени и контрольной группы. У больных на стадии стеатогепатита отмечалось существенное снижение Т-критерия в обеих зонах исследования. Распространенность остеопороза (ОП) и остеопении в первой и контрольной группах статистически не различалась. При стеатогепатите ОП выявлялся в два раза чаще, чем при стеатозе печени.</p></sec><sec><title>Выводы</title><p>Выводы. Представленные данные свидетельствуют, что в клинической картине НАЖБП доминирует астенический синдром. Полученные результаты исследования подтверждают коморбидное течение НАЖБП на стадии стеатогепатита и ОП.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>SUMMARY</title><p>SUMMARY</p><p>Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases. Its comorbid course with various diseases is noted. It has been established that bone disorders are often detected in NAFLD.</p></sec><sec><title>The purpose of the study</title><p>The purpose of the study. To clarify the effect of NAFLD on the condition of bone tissue, the dependence of changes in BMD and the severity of the pathological process in the liver.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. 98 women were examined, with an average age of 53.3±6.24 years. All individuals underwent a clinical examination, body mass index was calculated, ultrasound examination (ultrasound) of the abdominal cavity, two-energy X-ray absorptimetry of the lumbar spine (LS) and femoral neck (FN) with clarification of the value of the T-criterion, esophagogastroduodenoscopy, biochemical blood analysis were performed. All patients were divided into 3 groups: the first group consisted of 47 people with liver steatosis, the second group included 25 people with steatohepatitis. The control group included 26 women with the results of biochemical blood parameters within the reference values and unchanged liver ultrasound data. Results. The analysis of clinical symptoms showed the presence of asthenic syndrome/chronic fatigue in all patients with NAFLD, while the severity of symptoms increased with steatohepatitis. According to densitometry, the average values of the T-criterion in both SB and POP did not significantly differ in patients with liver steatosis and the control group. In patients with steatohepatitis, there was a significant decrease in the T-criterion in both study areas. The prevalence of osteoporosis (OP) and osteopenia in the first and control groups did not differ statistically. In steatohepatitis, OP was detected twice as often as in liver steatosis. </p></sec><sec><title>Conclusions</title><p>Conclusions. The presented data indicate that asthenic syndrome dominates the clinical picture of NAFLD. The results of the study confirm the comorbid course of NAFLD at the stage of steatohepatitis and OP.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>неалкогольная жировая болезнь печени</kwd><kwd>остеопороз</kwd><kwd>денситометрия</kwd><kwd>астенический синдром</kwd><kwd>минеральная плотность костной ткани</kwd></kwd-group><kwd-group xml:lang="en"><kwd>non-alcoholic fatty liver disease</kwd><kwd>osteoporosis</kwd><kwd>densitometry</kwd><kwd>asthenic syndrome</kwd><kwd>bone mineral density</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Povsic M., Wong O. Y., Perry R. et/ all/ Structured Literature Review of the Epidemiology and Disease Burden of NonAlcoholic Steatohepatitis (NASH). Adv Ther. 2019; 36(7):1574–94. DOI:10.1007/s12325-019-00960-3</mixed-citation><mixed-citation xml:lang="en">Povsic M., Wong O. Y., Perry R. et/ all/ Structured Literature Review of the Epidemiology and Disease Burden of NonAlcoholic Steatohepatitis (NASH). Adv Ther. 2019; 36(7):1574–94. DOI:10.1007/s12325-019-00960-3</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Basaranoglu M., Neuschwander-Tetri B. A. Nonalcoholic Fatty Liver Disease: Clinical Features and Pathogenesis. Gastroenterol Hepatol. 2006; 2(4): 282–291. PMID: 28286458; PMCID: PMC 5335683.</mixed-citation><mixed-citation xml:lang="en">Basaranoglu M., Neuschwander-Tetri B. A. Nonalcoholic Fatty Liver Disease: Clinical Features and Pathogenesis. Gastroenterol Hepatol. 2006; 2(4): 282–291. PMID: 28286458; PMCID: PMC 5335683.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Цуканов В. В., Осипенко М. Ф., Белобородова Е. В. с соавт. Практические аспекты клинических проявлений, патогенеза и терапии алкогольной болезни печени и неалкогольной жировой болезни печени: мнение экспертов. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2023;33(4):7–13. doi.org/10.22416/1382-4376-2023-33-4-7-13</mixed-citation><mixed-citation xml:lang="en">Tsukanov V. V., Osipenko M. F., Beloborodova E. V. et al. Practical Aspects of Clinical Manifestations, Pathogenesis and Therapy of Alcoholic Liver Disease and Non-alcoholic Fatty Liver Disease: Expert Opinion. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2023;33(4):7–13. https://doi.org/10.22416/1382-4376-2023-33-4-7-13</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Jichitu A., Bungau S., Stanescu A. M.A. et al. Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management. Diagnostics (Basel). 2021;11(4): 689. DOI:10.3390/diagnostics11040689</mixed-citation><mixed-citation xml:lang="en">Jichitu A., Bungau S., Stanescu A. M.A. et al. Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management. Diagnostics (Basel). 2021;11(4): 689. DOI:10.3390/diagnostics11040689</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Birkenfeld A. L., Shulman G. I. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology. 2014;59:713–23. DOI: 10.1002/hep.26672</mixed-citation><mixed-citation xml:lang="en">Birkenfeld A. L., Shulman G. I. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology. 2014;59:713–23. DOI: 10.1002/hep.26672</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Targher G., Byrne C. D. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat Rev Nephrol. 2017;13:297–310.DOI:10.1038/nrneph.2017.16</mixed-citation><mixed-citation xml:lang="en">Targher G., Byrne C. D. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat Rev Nephrol. 2017;13:297–310.DOI:10.1038/nrneph.2017.16</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ливзан М.А., Гаус О.В., Николаев Н.А. с соавт. НАЖБП: коморбидность и ассоциированные заболевания. Экспериментальная и клиническая гастроэнтерология. 2019;170(10): 57–65. DOI: 10.31146/1682-8658-ecg-170-10-57-65</mixed-citation><mixed-citation xml:lang="en">Livzan M. A., Gaus O. V., Nikolaev N. A. et al. NAFLD: comorbidity and associated diseases. Experimental and Clinical Gastroenterology. 2019;1(10):57–65. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-170-10-57-65</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Салихова С.Б., Каримов М.М., Собирова Г.Н. с соавт. Параметры минеральной плотности костной ткани при неалкогольной жировой болезни печени. Вестник врача. 2014;3:182–184. извлечено от https://inlibrary.uz/index.php/doctors_herald/article/view/4959;</mixed-citation><mixed-citation xml:lang="en">Salikhova S. B., Karimov M. M., Sobirova G. N. et al. Parameters of bone mineral density in non-alcoholic fatty liver disease. Bulletin of the doctor. 2014;3:182–184. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Очеретина Р. Ю. Взаимосвязь морфофункционального состояния печени с метаболизмом костной ткани. Успехи современного естествознания. 2015;2:89–93 URL: https://natural-sciences.ru/ru/article/view?id=34708 (дата обращения: 04.11.2024).</mixed-citation><mixed-citation xml:lang="en">Ocheretina R. Y. The relationship of the morphofunctional state of the liver with bone metabolism. The successes of modern natural science. 2015;2:89–93. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Chen HJ, Yang HY, Hsueh KC, et al. Increased risk of osteoporosis in patients with nonalcoholic fatty liver disease: A population-based retrospective cohort study. Medicine (Baltimore). 2018;97(42): e12835. DOI:10.1097/MD.0000000000012835</mixed-citation><mixed-citation xml:lang="en">Chen HJ, Yang HY, Hsueh KC, et al. Increased risk of osteoporosis in patients with nonalcoholic fatty liver disease: A population-based retrospective cohort study. Medicine (Baltimore). 2018;97(42): e12835. DOI:10.1097/MD.0000000000012835</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Белая Ж. Е., Рожинская Л. Я., Гребенникова Т. А. с соавт. Краткое изложение проекта федеральных клинических рекомендаций по остеопорозу. Остеопороз и остеопатии. 2020;23(2):4–21</mixed-citation><mixed-citation xml:lang="en">Belaya Zh.E., Rozhinskaya L. Y., Grebennikova T. A. et al. Summary of the draft federal clinical guidelines for osteoporosis. Osteoporosis and Bone Diseases. 2020;23(2):4–21. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Казакова В. С., Жилякова Е. Т., Новиков О. О. Перспективы использования факторов роста в восстановлении костной ткани. Обзор литературы. Научный результат. Серия Медицина и фармация. 2015; 1(3):151–158. DOI: 10.18413/2313-8955-2015-1-3-151-158</mixed-citation><mixed-citation xml:lang="en">Kazakova VS, Novikov ОО, Zhilyakova EТ, et al. Рrospects for the use of growth factors in bone tissue regeneration. Literature review. Research Result. Medicine and Pharmacy Series. 2015;1(3):151–158 (In Russ)]. DOI: 10.18413/2313-8955-2015-1-3-151-158</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Игнатенко Г. А., Немсадзе И. Г., Мирович Е. Д. с соавт. Роль цитокинов в ремоделировании костной ткани и патогенезе постменопаузального остеопороза. Медицинский вестник Юга России. 2020;11(2):6–18 DOI.org/10.21886/2219-8075-2020-11-2-6-18 Ignatenko G.A., Nemsadze I.G., Mirovich E.D. et al. The role of cytokines in bone remodeling and the pathogenesis of postmenopausal osteoporosis. Medical Herald of the South of Russia. 2020;11(2):6–18. (In Russ.) doi.org/10.21886/2219-8075-2020-11-2-6-18</mixed-citation><mixed-citation xml:lang="en">ИIgnatenko G.A., Nemsadze I.G., Mirovich E.D. et al. The role of cytokines in bone remodeling and the pathogenesis of postmenopausal osteoporosis. Medical Herald of the South of Russia. 2020;11(2):6–18. (In Russ.) doi.org/10.21886/2219-8075-2020-11-2-6-18</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Yuchen T., Shenghong W., Qiong Yi, et al. High-density Lipoprotein Cholesterol Is сorrelated with bone mineral density and has potential predictive value for bone loss. Lipids in Health and Disease. 2021; 20:75 doi.org/10.1186/s12944-021-01497-7</mixed-citation><mixed-citation xml:lang="en">Yuchen T., Shenghong W., Qiong Yi, et al. High-density Lipoprotein Cholesterol Is сorrelated with bone mineral density and has potential predictive value for bone loss. Lipids in Health and Disease. 2021; 20:75 doi.org/10.1186/s12944-021-01497-7</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ильющенко А. К., Мачехина Л. В., Стражеско И. Д. с cоавт. Роль ИФР-1/СТГ в процессах старения и развитии возраст-ассоциированных заболеваний. Ожирение и метаболизм. 2023;20(2):149–157. https://doi.org/10.14341/omet12934</mixed-citation><mixed-citation xml:lang="en">lyushchenko A.K., Machekhina L. V., Strazhesko I. D. et al. The role of IGF-1/GH in the aging process and the development of age-related diseases. Obesity and metabolism. 2023;20(2):149–157. (In Russ.) https://doi.org/10.14341/omet12934</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Yuan S, Wan ZH, Cheng SL et al. Insulin-like Growth Factor-1, Bone Mineral Density, and Fracture: A Mendelian Randomization Study. J Clin Endocrinol Metab 2021; 106(4): e1552-e1558. doi: 10.1210/clinem/dgaa963.</mixed-citation><mixed-citation xml:lang="en">Yuan S, Wan ZH, Cheng SL et al. Insulin-like Growth Factor-1, Bone Mineral Density, and Fracture: A Mendelian Randomization Study. J Clin Endocrinol Metab 2021; 106(4): e1552-e1558. doi: 10.1210/clinem/dgaa963.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Reinehr T., Woelfle J., Wunsch R. et al. Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: A longitudinal analysis. The Journal of Clinical Endocrinology and Metabolism. 2012;97(6):2143–2150. doi: 10.1210/jc.2012-1221.</mixed-citation><mixed-citation xml:lang="en">Reinehr T., Woelfle J., Wunsch R. et al. Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: A longitudinal analysis. The Journal of Clinical Endocrinology and Metabolism. 2012;97(6):2143–2150. doi: 10.1210/jc.2012-1221.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Florén CH, Chen CH, Franzén J. et al. Lecithin: cholesterol acyltransferase in liver disease.. Scand J Clin Lab Invest 1987; 47(6):613–7. doi: 10.1080/00365518709168477.</mixed-citation><mixed-citation xml:lang="en">Florén CH, Chen CH, Franzén J. et al. Lecithin: cholesterol acyltransferase in liver disease.. Scand J Clin Lab Invest 1987; 47(6):613–7. doi: 10.1080/00365518709168477.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Nardo A. D., Grun N. G., Zeyda M.et all Impact of osteopontin on the development of nonalcogolic liver disease and related hepatocellular carcinoma Liver Int. 2020; 40 (7): 1620–1633ю doi: 10.1111liv.14464</mixed-citation><mixed-citation xml:lang="en">Nardo A. D., Grun N. G., Zeyda M.et all Impact of osteopontin on the development of nonalcogolic liver disease and related hepatocellular carcinoma Liver Int. 2020; 40 (7): 1620–1633ю doi: 10.1111\liv.14464</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Yilmaz Y, Yonal O, Kurt R. et al. Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease. Scand J Clin Lab Invest. 2010;70(8):541–6. doi: 10.3109/00365513.2010.524933.</mixed-citation><mixed-citation xml:lang="en">Yilmaz Y, Yonal O, Kurt R. et al. Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease. Scand J Clin Lab Invest. 2010;70(8):541–6. doi: 10.3109/00365513.2010.524933.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Moser S. C., van der Eerden. Osteocalcin – A Versatile Bone-Derived Hormone Citation: BCJ. Endocrinol. 2019;9:794. doi: 10.3389/fendo.2018.00794</mixed-citation><mixed-citation xml:lang="en">Moser S. C., van der Eerden. Osteocalcin – A Versatile Bone-Derived Hormone Citation: BCJ. Endocrinol. 2019;9:794. doi: 10.3389/fendo.2018.00794</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Otani T., Mizocami A., Kawakudo-Yasukochi T et al. The roles of osteocalcin in lipid metabolism in adipose tissue and liver Adv. Biol. Rehul. 2020;78:100762 doi 10.1016j.jbior.2020.100762</mixed-citation><mixed-citation xml:lang="en">Otani T., Mizocami A., Kawakudo-Yasukochi T et al. The roles of osteocalcin in lipid metabolism in adipose tissue and liver Adv. Biol. Rehul. 2020;78:100762 doi 10.1016\j.jbior.2020.100762</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Ruhi K., Saif Q., Haque S. F. et al. TNF-α is an Inflammatory Marker of Cardiovascular Risks in Non-Alcoholic Fatty Liver Disease. J Clin Diagn Res. 2011;5(6):1237–1240. DOI: 10.7860/JCDR/2011/.1621.</mixed-citation><mixed-citation xml:lang="en">Ruhi K., Saif Q., Haque S. F. et al. TNF-α is an Inflammatory Marker of Cardiovascular Risks in Non-Alcoholic Fatty Liver Disease. J Clin Diagn Res. 2011;5(6):1237–1240. DOI: 10.7860/JCDR/2011/.1621.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Ilias D., Vachliotis М., Stergios A. The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease. Curr Obes Rep. 2023; 12(3):191–206. doi: 10.1007/s13679-023-00519.</mixed-citation><mixed-citation xml:lang="en">Ilias D., Vachliotis М., Stergios A. The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease. Curr Obes Rep. 2023; 12(3):191–206. doi: 10.1007/s13679-023-00519.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Yao Z., Stephen J. Getting J. et al. Regulation of TNF-Induced Osteoclast Differentiation. Cells. 2022;11(1):132. DOI: 10.3390/cells11010132</mixed-citation><mixed-citation xml:lang="en">Yao Z., Stephen J. Getting J. et al. Regulation of TNF-Induced Osteoclast Differentiation. Cells. 2022;11(1):132. DOI: 10.3390/cells11010132</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Тополянская С. В. Фактор некроза опухоли-альфа и возраст-ассоциированная патология. Архивъ внутренней медицины. 2020; 10(6): 414–421. DOI: 10.20514/2226-6704-2020-10-6-414-421</mixed-citation><mixed-citation xml:lang="en">Topolyanskaya S. V. Tumor Necrosis Factor-Alpha and Age-Related Pathologies. The Russian Archives of Internal Medicine. 2020;10(6): 414–421. DOI: 10.20514/2226-6704-202 0-10-6-414-421.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Мальцев С. В. Современные данные о витамине D – метаболизм, роль в организме, особенности применения в практике врача. Практическая медицина. 2020; 18 (4): 8–22. DOI: 10.32000/2072-1757-2020-4-8-22</mixed-citation><mixed-citation xml:lang="en">Maltsev S. V. Modern data on vitamin D – metabolism, role in the organism, and features of application in a doctor’s practice. Practical medicine. 2020; 18(4): 8–22. (in Russ). DOI: 10.32000/2072-1757-2020-4-8-22</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Targher G, Bertolini L, Scala L, et al. Associations between serum 25-hydroxyvitamin D 3 concentrations and liver histology in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2007;17:517–24. DOI: 10.1016/j.numecd.2006.04.002</mixed-citation><mixed-citation xml:lang="en">Targher G, Bertolini L, Scala L, et al. Associations between serum 25-hydroxyvitamin D 3 concentrations and liver histology in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2007;17:517–24. DOI: 10.1016/j.numecd.2006.04.002</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Gad A. I., Elmedames M. R., Abdelhai A. R. et al. The association between vitamin D status and non-alcoholic fatty liver disease in adults: a hospital-based study. Egyptian Liver Journal 2020;10:25–31 doi.org/10.1186/s43066-020-00033-z</mixed-citation><mixed-citation xml:lang="en">Gad A. I., Elmedames M. R., Abdelhai A. R. et al. The association between vitamin D status and non-alcoholic fatty liver disease in adults: a hospital-based study. Egyptian Liver Journal 2020;10:25–31 doi.org/10.1186/s43066-020-00033-z</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Кузнецова Е. А., Есауленко Е. Е., Быков И. М. Биохимические механизмы развития дефицита тестостерона у мужчин с неалкогольной жировой болезнью печени. Крымский журнал экспериментальной и клинической медицины. 2021;11(4):98–105 DOI: 10.3727 9/2224-6444-2021-11-4-98-105</mixed-citation><mixed-citation xml:lang="en">Kuznetsova E. A., Esaulenko E. E., Bykov I. M. Biochemical mechanisms of testosterone deficiency in men with non-alcoholic fatty liver disease. Crimean Journal of Experimental and Clinical Medicine. 2021;11(4):98–105 DOI: 10.37279/2224-6444-2021-11-4-98-105</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Fink H. A., Ewing S. K., Ensrud K. E. et al. Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab. 2006; 91(10): 3908–15. doi: 10.1210/ jc.2006–0173.</mixed-citation><mixed-citation xml:lang="en">Fink H. A., Ewing S. K., Ensrud K. E. et al. Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab. 2006; 91(10): 3908–15. doi: 10.1210/ jc.2006–0173.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Гальченко А. В. Влияние факторов образа жизни на метаболизм костной ткани и риск развития остеопороза. Профилактическая медицина. 2022;25(6):96–107. doi.org/10.17116/profmed20222506196.</mixed-citation><mixed-citation xml:lang="en">Galchenko AV. Influence of lifestyle factors on bone metabolism and the risk of osteoporosis. Russian Journal of Preventive Medicine. 2022;25(6):96–107. (In Russ.) doi.org/10.17116/profmed20222506196.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Rosato V, Masarone M, Dallio M, et al. NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome. Int J Environ Res Public Health. 2019;16(18):3415. DOI: 10.3390/ijerph16183415).</mixed-citation><mixed-citation xml:lang="en">Rosato V, Masarone M, Dallio M, et al. NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome. Int J Environ Res Public Health. 2019;16(18):3415. DOI: 10.3390/ijerph16183415).</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Filip R, Radzki RP, Bieńko M. Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis. Clin Interv Aging. 2018;13:1879–91. DOI:10.2147/CIA.S 170533</mixed-citation><mixed-citation xml:lang="en">Filip R, Radzki RP, Bieńko M. Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis. Clin Interv Aging. 2018;13:1879–91. DOI: 10.2147/CIA.S 170533</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Фомина Л. А., Зябрева И. А. Гендерные аспекты остеопороза и их связь с кальциевым балансом. Казанский медицинский журнал. 2017; 98(3): 343–348. DOI: 10.17750/KMJ2017-343</mixed-citation><mixed-citation xml:lang="en">Fomina L. A., Zyabreva I. A. Gender aspects of osteoporosis and their relationship to calcium balance. Kazan medical journal. 2017; 98(3): 343–348. (in Russ). doi: 10.17750/KMJ2017-343</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
